Sterling Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Sterling Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.3M	Sell	8,648 -4,690	-35%	-$2.08M	0.07%	224
2026 Q1	$5.96M	Sell	13,338 -4,204	-24%	-$1.96M	0.11%	165
2025 Q4	$7.95M	Buy	17,542 +64	+0.4%	+$27.6K	0.13%	133
2025 Q3	$6.85M	Sell	17,478 -2,966	-15%	-$1.24M	0.1%	130
2025 Q2	$9.1M	Buy	20,444 +8,070	+65%	+$3.72M	0.13%	107
2025 Q1	$6M	Buy	12,374 +375	+3%	+$175K	0.09%	126
2024 Q4	$4.83M	Sell	11,999 -291	-2%	-$135K	0.07%	227
2024 Q3	$5.72M	Buy	+12,290	New	+$5.9M	0.07%	184
2017 Q3	–	Sell	-2,020	Closed	-$260K	–	980
2017 Q2	$260K	Buy	+2,020	New	+$243K	﹤0.01%	848
2014 Q3	–	Sell	-2,911	Closed	-$276K	–	961
2014 Q2	$276K	Buy	+2,911	New	+$204K	﹤0.01%	820

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Sterling Capital Management's VRTX Position: Q2 2026 in Review

Sterling Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 35% in Q2 2026, selling an estimated $2.08M and leaving 8,648 shares worth $4.3M. The position accounts for 0.07% of the portfolio, ranked #224.

Sterling Capital Management first reported a position in VRTX in Q2 2014 and has held it in 10 quarters since. The position peaked at $9.1M in Q2 2025. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Sterling Capital Management held 8,648 shares of Vertex Pharmaceuticals worth $4.3M as of Q2 2026.
Sterling Capital Management sold 4,690 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.08M.
Vertex Pharmaceuticals made up 0.07% of Sterling Capital Management's portfolio in Q2 2026, its #224 holding.
Sterling Capital Management first reported a position in Vertex Pharmaceuticals in Q2 2014 and has held it in 10 quarters since.
Sterling Capital Management's Vertex Pharmaceuticals position peaked at $9.1M in Q2 2025.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.